Vaccine Research. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain.
Vaccine Research. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain; Universidad Católica de Valencia San Vicente Mártir, Carrer de Quevedo, 2, 46001 València, Spain.
J Infect. 2018 Aug;77(2):131-136. doi: 10.1016/j.jinf.2018.04.004. Epub 2018 May 6.
To estimate the incidence and burden of postherpetic neuralgia (PHN) and to investigate risk factors for PHN in the Valencia Region of Spain.
Data were extracted from population and healthcare databases from the Valencia Region (2009-2014). Herpes zoster (HZ) and PHN were defined using ICD-9 codes and drug prescriptions in people aged ≥50 years. The risk of HZ patients for developing PHN and potential risk factors (diabetes mellitus, COPD and heart failure) were investigated. A survival analysis was developed to estimate the cumulative hazard of developing HZ and PHN between ages 50-90 years.
From a total of 2,289,485 subjects, 87,086 cases of HZ were registered, 13,658 (15.7%) of whom developed PHN. PHN risk was higher in women and increased sharply with age and comorbidities as diabetes mellitus, COPD and heart failure. The cumulative risk of developing HZ between ages 50-90 years was 31.7% (95% CI: 31.3-32.1) and 6.9 (95% CI: 6.7-7.1) for PHN.
PHN risk was higher in women and increased with age and comorbidities. At least 32% and 7% of people will develop HZ and PHN, respectively, between ages 50-90 years. These results should be considered for vaccine policy implementation.
估计带状疱疹后神经痛（PHN）的发病率和负担，并研究西班牙巴伦西亚地区 PHN 的危险因素。
从巴伦西亚地区的人群和医疗保健数据库中提取数据（2009-2014 年）。≥50 岁人群中使用 ICD-9 编码和药物处方定义带状疱疹（HZ）和 PHN。调查 HZ 患者发生 PHN 的风险以及潜在危险因素（糖尿病、COPD 和心力衰竭）。采用生存分析估计 50-90 岁人群中发生 HZ 和 PHN 的累积发病风险。
在总共 2289485 名受试者中，登记了 87086 例 HZ 病例，其中 13658 例（15.7%）发展为 PHN。女性的 PHN 风险较高，且随年龄和合并症（如糖尿病、COPD 和心力衰竭）急剧增加。50-90 岁人群中发生 HZ 的累积风险为 31.7%（95%CI：31.3-32.1），发生 PHN 的风险为 6.9（95%CI：6.7-7.1）。
女性的 PHN 风险较高，且随年龄和合并症增加而增加。至少 32%和 7%的人在 50-90 岁之间分别会发生 HZ 和 PHN。这些结果应在疫苗政策实施中加以考虑。
